background
viral
caus
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
well
recognis
recent
rapid
test
becom
avail
aim
identifi
respiratori
virus
gener
popul
associ
hospitalis
aecopd
use
polymeras
chain
reaction
pcr
nasopharyng
aspir
npa
relationship
symptom
viral
detect
inflammatori
marker
method
review
virus
detect
gener
popul
health
district
august
juli
use
multiplex
pcr
virus
npa
sampl
addit
singl
hospit
retrospect
audit
patient
admit
suspect
aecopd
conduct
npa
test
posit
least
one
viru
obtain
adult
adult
common
virus
identifi
influenza
rhinoviru
respiratori
syncyti
viru
ab
patient
aecopd
npa
sent
viral
pcr
test
posit
common
virus
identifi
influenza
rhinoviru
respiratori
syncyti
viru
ab
coinfect
bacteria
cultur
sputum
sampl
patient
influenzalik
symptom
like
posit
viral
pcr
without
symptom
p
median
creactiv
protein
admiss
lower
virusinfect
uninfect
aecopd
vs
mgl
p
spectrum
virus
detect
patient
aecopd
similar
gener
popul
virus
like
identifi
patient
aecopd
present
influenzalik
symptom
low
creactiv
protein
chronic
obstruct
pulmonari
diseas
copd
constitut
major
health
problem
australia
acut
exacerb
copd
aecopd
consider
impact
morbid
mortal
qualiti
life
common
trigger
aecopd
includ
air
pollut
infect
virus
andor
bacteria
tracheobronchi
tree
howev
least
onethird
sever
exacerb
caus
identifi
antibiot
therapi
wide
sometim
inappropri
use
aecopd
result
increas
risk
advers
effect
increas
antibiot
resist
antivir
therapi
influenza
virus
avail
need
commenc
soon
develop
symptom
antivir
agent
virus
includ
antirhinovir
agent
clinic
develop
yet
avail
routin
use
previou
longitudin
communitybas
hospitalis
studi
show
viral
infect
common
patient
aecopd
usual
associ
sever
present
longer
median
symptom
recoveri
compar
nonvir
exacerb
virus
detect
upper
respiratori
tract
frequent
picornavirus
human
rhinoviru
hrv
influenza
respiratori
syncyti
viru
rsv
fund
none
conflict
interest
none
viral
caus
aecopd
well
recognis
sensit
rapid
test
common
respiratori
virus
recent
use
wide
clinic
set
comparison
differ
diagnost
method
detect
respiratori
virus
includ
viral
cultur
antigen
detect
test
serolog
revers
transcriptas
pcr
shown
nucleic
acid
test
nat
pcr
sensit
least
equal
specif
pcr
techniqu
use
nasopharyng
aspir
npa
swab
time
higher
diagnost
yield
convent
viral
cultur
thu
wide
use
south
eastern
sydney
laboratori
servic
seal
refer
virolog
laboratori
princ
wale
hospit
powh
past
year
screen
tool
viral
respiratori
tract
infect
given
time
npa
sampl
nat
assay
avail
result
altern
sensit
potenti
less
specif
marker
differenti
viral
bacteri
respiratori
infect
would
benefici
guid
initi
therapi
creactiv
protein
crp
acut
phase
protein
increas
infecti
inflammatori
condit
crp
level
shown
increas
aecopd
well
correl
sever
outcom
studi
examin
relationship
microbi
aetiolog
crp
level
patient
aecopd
within
powh
singl
centr
sydney
eastern
suburb
local
health
district
seslhd
respiratori
patient
present
emerg
depart
ed
like
requir
admiss
symptom
suggest
viral
respiratori
tract
infect
annual
influenza
season
undergo
npa
viral
pcr
isol
result
avail
group
patient
signific
proport
underli
copd
patient
commenc
antimicrobi
treatment
base
clinic
criteria
aecopd
would
help
earli
indic
viral
infect
either
direct
identif
virus
surrog
would
allow
appropri
treatment
isol
patient
aim
studi
assess
respiratori
virus
associ
hospitalis
aecopd
identifi
npa
viral
pcr
test
relationship
viral
detect
inflammatori
marker
coexist
organ
retrospect
case
studi
design
approv
seslhd
ethic
committe
two
audit
conduct
studi
time
period
detail
npa
request
gener
popul
within
one
local
health
district
specif
group
patient
admit
singl
hospit
local
health
district
audit
perform
upon
databas
npa
submit
viral
pcr
seslhd
depart
virolog
serolog
savid
seal
microbiolog
august
juli
subject
age
group
test
request
primari
healthcar
outpati
inpati
set
baselin
characterist
comorbid
indic
test
avail
cohort
separ
detail
audit
perform
medic
record
patient
admit
aecopd
period
octob
septemb
respiratori
physician
powh
sydney
met
inclus
criteria
inclus
criteria
age
year
ii
previou
diagnosi
copd
spirometri
perform
admiss
reveal
fev
fvc
iii
symptom
aecopd
per
gold
definit
worsen
patient
respiratori
symptom
beyond
normal
daytoday
variat
lead
chang
medic
gold
definit
aecopd
refer
acut
chang
one
follow
cardin
symptom
increas
cough
frequencysever
increas
sputum
volum
chang
charact
increas
dyspnoea
sever
copd
defin
gold
criteria
mild
fev
predict
moder
fev
sever
sever
fev
audit
base
definit
influenzalik
symptom
local
guidelin
viral
npa
test
follow
ed
patient
present
fever
c
plu
one
coryz
symptom
myalgia
headach
electron
patholog
databas
search
result
viral
npa
pcr
crp
sputum
microscopi
cultur
specimen
request
within
first
h
arriv
hospit
similarli
chest
xray
report
present
review
presenc
parenchym
collapseconsolid
note
commenc
empir
antibiot
antivir
agent
ed
record
document
confirm
indic
treatment
aecopd
instruct
isol
patient
droplet
precaut
admiss
record
document
emerg
staff
seslhd
virolog
databas
contain
npa
viral
pcr
result
interrog
show
posit
result
year
august
juli
fig
posit
result
npa
obtain
adult
posit
least
one
virus
graph
figur
common
virus
identifi
adult
allcom
popul
influenza
rhinoviru
rsv
ab
fig
profil
virus
patient
less
year
age
significantli
differ
adult
group
medic
record
singl
centr
within
seslhd
powh
found
patient
admit
aecopd
similar
period
clincial
characterist
patient
shown
tabl
cohort
mean
age
year
rang
prior
index
present
copd
previous
recognis
patient
spirometri
initi
perform
major
classifi
sever
copd
remain
patient
found
obstruct
spirometri
present
consist
copd
howev
spirometr
data
exclud
signific
bronchial
revers
avail
asthma
could
exclud
npa
n
sent
viral
pcr
posit
common
virus
identifi
influenza
rhinoviru
rsv
ab
fig
multipl
virus
identifi
three
patient
posit
viral
pcr
coinfect
includ
influenza
brhinoviruscoronaviru
rsvcoronaviru
rhinoviruscoronaviru
posit
npa
cultur
coexist
bacteria
sputum
test
within
h
admiss
common
bacteria
fungi
cultur
includ
pseudomona
aeruginosa
haemophilu
influenza
aspergillu
speci
influenzalik
symptom
fever
plu
one
coryz
symptom
myalgia
headach
report
patient
present
ed
underw
viral
npa
pcr
test
fig
influenzalik
symptom
statist
like
posit
viral
npa
pcr
without
symptom
p
valu
chisquar
test
sever
copd
abl
estim
patient
posit
viral
pcr
major
patient
admit
met
gold
criteria
sever
sever
copd
relat
likelihood
viral
posit
crp
request
approxim
twothird
patient
present
ed
aecopd
posit
viral
pcr
mean
crp
highest
rsv
ab
mgl
follow
rhinoviru
mgl
influenza
mgl
median
crp
admiss
lower
patient
viral
versu
nonvir
aecopd
mgl
vs
mgl
p
valu
mannwhitney
radiolog
review
evid
consolid
found
posit
viral
npa
pcr
neg
season
trend
posit
viral
pcr
result
seslhd
databas
reflect
peak
week
august
august
laboratori
notif
influenza
nsw
flu
season
posit
influenza
pcr
result
august
juli
confirm
month
august
alon
base
initi
clinic
histori
examin
radiolog
find
patient
aecopd
isol
droplet
precaut
per
influenza
season
protocol
ed
patient
found
posit
viral
pcr
aecopd
acut
exacerb
chronic
obstruct
pulmonari
diseas
copd
chronic
obstruct
pulmonari
diseas
crp
creactiv
protein
cxr
npa
nasopharyng
aspir
group
patient
initi
isol
found
posit
viral
pcr
patient
commenc
empir
antibiot
aecopd
posit
viral
pcr
minor
patient
patient
commenc
empir
oseltamivir
posit
viral
pcr
studi
retrospect
examin
relationship
present
symptom
inflammatori
marker
microbiolog
result
patient
present
singl
centr
aecopd
introduct
viral
npa
pcr
test
demonstr
detect
rate
respiratori
virus
strongli
associ
low
crp
level
influenzalik
symptom
present
compar
powh
aecopd
data
wider
health
district
seslhd
similar
time
period
interest
observ
drawn
microbiolog
profil
virus
identifi
adult
group
similar
reveal
influenza
common
viru
isol
regardless
underli
copd
follow
rhinoviru
rsv
coronavirida
would
inform
establish
proport
patient
copd
powh
group
receiv
annual
influenza
vaccin
prior
present
inform
rare
record
medic
record
compar
gener
popul
captur
seslhd
data
one
would
expect
risk
group
protect
influenza
greater
vaccin
rate
viral
bacteri
infect
trigger
aecopd
case
coinfect
bacteria
virus
patient
suggest
class
organ
play
role
studi
asthma
exacerb
appear
like
respiratori
virus
princip
initi
infect
initi
bacteri
infect
lesser
import
reason
behind
lower
rate
viral
detect
exacerb
copd
compar
asthma
unclear
overal
detect
rate
studi
slightli
higher
similar
studi
would
appear
like
viral
infect
disrupt
airway
epithelium
reduc
innat
immun
allow
bacteri
secondari
infect
occur
previous
describ
surrog
marker
discrimin
viral
nonvir
aecopd
review
audit
symptom
inflammatori
marker
found
potenti
use
indic
current
guidelin
regard
influenzalik
symptom
found
strongli
associ
posit
viral
result
thu
appear
support
clinic
assess
key
aspect
histori
obtain
present
triag
studi
associ
influenzalik
symptom
rate
droplet
precaut
isol
proven
viral
infect
would
determin
necess
isol
protocol
patient
public
health
interest
prevent
inhospit
spread
previou
studi
aecopd
shown
patient
increas
sputum
purul
pattern
increas
crp
similar
seen
patient
pneumonia
suggest
crp
may
use
marker
signific
bacteri
infect
may
role
determin
whether
antimicrobi
prescrib
crp
level
significantli
lower
patient
viral
aecopd
support
contributori
role
serum
marker
establish
aetiolog
aecopd
potenti
guid
treatment
previou
copd
studi
coinfect
appear
increas
sever
exacerb
associ
symptom
higher
bacteri
load
system
inflamm
find
implic
treatment
newli
acquir
virus
may
initi
agent
one
studi
suggest
antibiot
may
minimis
interact
chronic
colonis
bacteria
viru
would
result
increas
bacteri
load
phenotyp
chang
howev
argument
need
weigh
potenti
empir
antibiot
caus
antimicrobi
resist
alreadi
vulner
popul
audit
found
symptom
marker
inflamm
inform
identifi
caus
aecopd
owe
studi
design
limit
attribut
causat
virus
detect
aecopd
first
viral
infect
may
miss
onethird
patient
test
present
presum
due
lack
influenzalik
symptom
viral
shed
occur
sever
week
postinfect
routin
test
subject
may
affect
studi
find
includ
associ
symptom
inflammatori
marker
second
potenti
select
bia
relat
indic
viral
test
exist
two
cohort
limit
capac
compar
data
set
aecopd
cohort
highli
select
group
patient
mani
symptom
suggest
viral
infect
prompt
test
comparison
indic
test
seslhd
cohort
unknown
like
variabl
includ
screen
infect
control
futur
prospect
studi
could
address
whether
crp
perhap
procalcitonin
could
use
addit
clinic
acumen
guid
empir
antimicrobi
use
aecopd
likewis
larg
control
trial
patient
randomis
receiv
empir
antimicrobi
target
viral
therapi
alon
suspect
viral
aecopd
may
identifi
subgroup
would
benefit
antimicrobi
treatment
audit
found
spectrum
virus
detect
upper
respiratori
tract
patient
present
aecopd
similar
gener
adult
popul
amongst
aecopd
cohort
virus
appear
like
identifi
present
influenzalik
symptom
low
crp
find
support
potenti
role
symptom
inflammatori
marker
determin
aetiolog
guid
empir
manag
aecopd
given
preval
influenza
aecopd
cohort
widespread
vaccin
may
help
protect
patient
prevent
hospit
admiss
